WESTFORD, Mass., March 15, 2012 /PRNewswire/ -- Cynosure,
Inc. (NASDAQ: CYNO), a leader in laser- and light-based treatments
for minimally invasive and non-invasive aesthetic applications,
today announced it plans to introduce a speed and power enhancement
for two of its most popular multi-purpose systems. The Company
expects to launch the Elite™+ and Apogee™+ Aesthetic
Workstations at the 70th Annual Meeting of the American Academy of
Dermatology March 16-20 in
San Diego, California.
"With enhanced power, these new workstations can treat 44
percent more area per pulse than our current Elite and Apogee
models," said Michael Davin,
Cynosure's President and Chief Executive Officer. "The increased
speed of treatment translates into higher patient throughput for
practitioners and reduced treatment time for patients, while
ensuring the safety, comfort and reliability that patients depend
on. These next-generation systems demonstrate our focus on
delivering innovative technology improvements that enable
practitioners to provide the most comprehensive suite of products
for applications that are in high demand."
Elite+ is a multi-purpose, dual-wavelength system used to remove
unwanted hair, treat facial and leg veins and rejuvenate the skin
by removing age spots and sun-damage -- all in a single visit. The
revolutionary technology of the Elite+ combines two optimal
wavelengths in one system: the 755-nm Alexandrite and the 1064-nm
Nd:YAG. Practitioners can switch between wavelengths during a
single procedure, allowing them to select the most appropriate
laser for any hair or skin type.
Apogee+ is equipped with a 755-nm Alexandrite laser that
permanently removes hair on a wide variety of skin types. In
addition, it treats benign epidermal pigmented lesions such as age
spots, sunspots and freckles. Current U.S. customers will be
able to upgrade their existing Elite and Apogee workstations to the
plus versions.
In addition to these enhanced workstations at AAD, Cynosure
(Booth # 3707) is featuring its new Cellulaze™
Workstation, the world's only FDA-cleared, minimally invasive
aesthetic device for cellulite reduction. Cellulaze reduces
cellulite in just one treatment by restoring the normal structure
of the skin and underlying connective tissue. It is designed to
diminish the lumpy pockets of fat, release the areas of skin
depression typifying cellulite and increase the elasticity and
thickness of the skin.
About Cynosure, Inc.
Cynosure, Inc. develops and markets aesthetic treatment
systems that are used by physicians and other practitioners to
perform non-invasive and minimally invasive procedures to remove
hair, treat vascular and pigmented lesions, rejuvenate the skin,
liquefy and remove unwanted fat through laser lipolysis, reduce the
appearance of cellulite and treat Onychomycosis. Cynosure's
products include a broad range of laser- and other light-based
energy sources, including Alexandrite, pulse dye, Q-switched,
Nd:YAG and diode lasers, as well as intense pulsed light. Cynosure
was founded in 1991. For corporate or product information, contact
Cynosure at 800-886-2966, or visit www.cynosure.com.
Forward-Looking Statements
Any statements in this press release about future
expectations, plans and prospects for Cynosure, Inc., including
statements about the Apogee+, Elite+ and Cellulaze, as well as
other statements containing the words "believes," "anticipates,"
"plans," "expects," "will" and similar expressions, constitute
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors, including the global
economy and lending environment and their effects on the aesthetic
laser industry, Cynosure's history of operating losses, its
reliance on sole source suppliers, the inability to accurately
predict the timing or outcome of regulatory decisions, changes in
consumer preferences, competition in the aesthetic laser industry,
economic, market, technological and other factors discussed in
Cynosure's most recent Annual Report on Form 10-K, which is filed
with the Securities and Exchange Commission. In addition, the
forward-looking statements included in this press release represent
Cynosure's views as of the date of this press release. Cynosure
anticipates that subsequent events and developments will cause its
views to change. However, while Cynosure may elect to update these
forward-looking statements at some point in the future, it
specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as
representing Cynosure's views as of any date subsequent to the date
of this press release.
Contact:
Scott Solomon
Vice President
Sharon Merrill Associates, Inc.
617.542.5300
cyno@investorrelations.com
SOURCE Cynosure, Inc.